Officer Files Intent to Sell $148K in Shares, Adding to Recent $266K Sales Amidst Financial Distress
CVKD is trading near its 52-week low of $3.265 (3.8% above the low).
Summary
An officer of Cadrenal Therapeutics has filed a Form 144 to sell 40,000 shares worth $148,400, following recent sales of $266,477, signaling continued insider distribution amidst the company's financial challenges.
Key Events · Ownership and Investor Activity · CVKD
-
Officer Files Intent to Sell Shares
Quang X. Pham, an officer of Cadrenal Therapeutics, filed a Form 144 indicating an intent to sell 40,000 common shares with an approximate market value of $148,400. The proposed sale date is June 15, 2026.
-
Ongoing Insider Distribution
This proposed sale follows recent sales by the same officer of 59,708 shares, generating gross proceeds of $266,477.56 over the past three months, indicating a pattern of insider selling.
-
Selling Amidst Financial Challenges
The selling activity occurs as the company faces a reiterated going concern warning and a limited cash runway only into October 2026. The stock is also trading near its 52-week low of $3.265.
Analysis · CVKD · Life Sciences
The intent to sell by officer Quang X. Pham for $148,400, combined with over $266,000 in sales in the past three months, represents a significant insider distribution for a company with a market cap of approximately $9.5 million. This ongoing selling, especially while the stock is near its 52-week low and the company has a going concern warning and limited cash runway, suggests a lack of insider confidence and could put further pressure on the stock price.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.4% of the 1304 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CVKD was trading at $3.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.6M. The 52-week trading range was $3.27 to $14.69. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.